Abstract:213 Background: Microsatellite stable/tumor mutational burden-low (MSS/TMB-L) tumors, represent the majority of colorectal cancer (CRC) patients and derive limited benefit from immune checkpoint inhibitors (ICI). Given the vast heterogeneity of this population, some patients may be candidates for ICI. Herein, we study the tumor immune microenvironment (TIME) and genomic correlates associated with favorable immune response in MSS/ TMB-L CRC patients. Methods: Using The Cancer Genomic Atlas Colorectal Adenocarcinoma (TCGA-COAD) cohort (n = 594), MSS patients (MSI Mantis score < 0.4) with TMB-L (<10 mutations/megabase) were identified. The CIBERSORT algorithm was used to calculate the fraction of 22 immune cells using RNA-seq data. Relevant immune expression signatures from the CRI iAtlas were used to assess TIME profiles. An antitumor immune activity (AIA) score was constructed using CD8+ T cells, T regulatory cells, and M1 & M2 macrophage fractions. Enriched mutations in MSS/ TMB-L patients with favorable antitumor immune scores were identified and used to stratify patients into favorable and unfavorable immune profiles (FIP & UIP). Comparisons were made using the Mann-Whitney U T-test and Fisher’s exact test. Results: We identified 430 (72.4%) MSS/TMB-L patients among the TCGA-COAD cohort. The AIA score ranged from – 0.44 to 0.62 (higher scores denote favorable AIA activity). The majority of patients (77%) had scores < 0. Top enriched mutated genes associated with higher scores included HMX2, BBS12, IFNLR1, SLC30A2, WDR48, ZNF329, H4C11, PARD3B, ENAM, ASCC1, CCDC88B, CMKLR1, IL21, KLHL11, and OTOP2. Patients harboring a mutation in one or more of these 15 genes were categorized in the FIP group (n=50, 11.6%) and patients with no mutations were categorized in the UIP group (n=360, 88.4%). The FIP group had significantly (p < 0.05) higher levels of TMB, CD8+ T cells, activated NK cells, M1 macrophages, immunogenic SNV mutations, and cytotoxic activity while patients with UIP had higher levels (p < 0.05) of M2 macrophages, neutrophils, and a trend for higher regulatory T cells and TH17 cells. Gene set enrichment analysis showed upregulation of T cell proliferation, interferon signaling, and Fanconi anemia pathway in FIP. Compared to UIP, FIP patients had a trend for better disease-specific survival after adjustment for CC subtype (colon vs. rectum) and age (HR: 0.26, 95% CI: 0.06-1.09, p = 0.066). Conclusions: Findings from this analysis highlight a subset of MSS/TMB-L CRC patients, with features of favorable anti-tumor immune response and unique mutation profile, that might derive benefit from immunotherapy. Further investigation is underway to further explore the genomic correlates in this subset of patients.

FAT4 mutation as a potential predictive biomarker for immunotherapy combined with anti-angiogenic therapy in MSS metastatic colorectal cancer.

Clinical Value of FAT1 Mutations to Indicate the Immune Response in Colorectal Cancer Patients.

FAT1 Mutations in Colorectal Cancer Patients Are Associated with the Therapeutic Benefit of Immunotherapy.

Functional Domain Mutations in FAT4 Cadherin 21-34 Predicts Improved Prognosis in Gastric Cancer Patients: A Retrospective Study

Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis

Characterization of the Fatty Acid Metabolism in Colorectal Cancer to Guide Clinical Therapy

FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer

FAT4 Mutation is Related to Tumor Mutation Burden and Favorable Prognosis in Gastric Cancer

Prognostic Prediction and Immunotherapy Response Analysis of the Fatty Acid Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma

FAT1 Upregulation is Correlated with an Immunosuppressive Tumor Microenvironment and Predicts Unfavorable Outcome of Immune Checkpoint Therapy in Non-Small Cell Lung Cancer

A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors

Increased expression of FAT4 suppress metastasis of lung adenocarcinoma through regulating MAPK pathway and associated with immune cells infiltration

Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer

FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis

FAT4 expression in peripheral blood mononuclear cells is associated with prognosis and immune cell infiltration in hepatocellular carcinoma

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study

Correlation of exploration of immune profile and genomic with microsatellite stable/tumor mutational burden-low colorectal cancer.

Abstract 5133: Gastric cancer carrying FAT4 mutations associated with favorable prognosis in comparison to wild-type: Results from Real-World Cohorts

Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer

A Novel Prognostic Signatures Based on Metastasis- and Immune-Related Gene Pairs for Colorectal Cancer.

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy